ORTHO DROPPING OUT OF McDONNELL DOUGLAS SPACE SHUTTLE PROGRAM
ORTHO DROPPING OUT OF McDONNELL DOUGLAS SPACE SHUTTLE PROGRAM targeted at the production in space of an undisclosed pharmaceutical, the defense aerospace company announced in a Sept. 12 press release. Ortho signed an agreement with McDonnell Douglas in January 1980 for the production of an unnamed pharmaceutical product via McDonnell Douglas' electrophoresis operations in space (EOS) program. J&J indicated that the company has found that the product can more easily be produced on the ground. The EOS program involves a device that uses continuous flow electrophoresis that separates materials in solution by subjecting them to an electrical field. In background information on the program, McDonnell Douglas said that its analyses indicate the device "could, in a weightless environment, yield products in much higher quantities and purities than are possible on earth." McDonnell Douglas has conducted electrophoresis operation on six shuttle flights for Ortho. Following return of an August 1984 flight, an Ortho hormone separated by the electrophoresis process was found contaminated ("The Pink Sheet" Nov. 12, T&G-3). According to McDonnell Douglas, the contamination occurred during processing. The aerospace firm said it will continue to be actively involved with Ortho "in pursuing other pharmaceutical opportunities to process drugs in space." McDonnell Douglas also said it is "discussing potential new partnerships, both in the U.S. and internationally, for development, testing and marketing of new pharmaceuticals and biological materials processed in space." Although McDonnell Douglas has agreements with several other companies, such as DuPont, 3M, and Honeywell, the firm's only commercial venture with a pharmaceutical firm was limited to Ortho. McDonnell Douglas said that it is continuing to process materials in space for the Ortho product and that "selection of a new partner or partners for that development will be announced when appropriate." The firm commented: "We are continuing as scheduled, and we still expect that pharmaceuticals produced from these developments will be tested and on the market in the late 1980s."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth